Clinical Updates in the Management of Paroxysmal Nocturnal Hemoglobinuria With Patient Perspectives

Add-on activity

This activity includes a Powered by Patients™ interview.

Program Description

Treatment for paroxysmal nocturnal hemoglobinuria (PNH) includes supportive therapy, transfusions, and pharmacologic treatment with complement-blocking agents. Traditional complement inhibitors include those that target C5; however, patients may continue to require blood transfusions to manage anemia, and a subset of patients may remain symptomatic or experience breakthrough hemolysis.  Recent advancements in the management of PNH include approvals of a C3 inhibitor as well as an orally administered factor B inhibitor that provide additional treatment options for people living with PNH. This second webinar in a 3-part series will focus on the efficacy and safety data for current and emerging agents for treating PNH as well as the treatment approach. A Powered by Patients™ interview will be incorporated into the activity to highlight the treatment journey for a person living with PNH.

Target audience: Health-system and specialty pharmacists

Type of activity: Application
Release date: June 4, 2024
Expiration date: June 4, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain safety and efficacy data on existing and emerging treatment options for the management of paroxysmal nocturnal hemoglobinuria (PNH)
• Compare traditional and emerging PNH therapies from a patient-centered perspective considering the impact on transfusion burden
• Construct evidence-based treatment algorithms integrating emerging complement inhibitors into the overall management of PNH

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-169-H01-P. The activity is available for CE credit through June 4, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Leslie Ward, PharmD, BCPS, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms